Keros Therapeutics, Inc. (KROS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Keros Therapeutics, Inc. (KROS) stock forecast summary
Our AI ranks Keros Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Keros Therapeutics, Inc. is a small-cap company with a market capitalization of $223M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 0.85x is the lowest of the 43 peers that report one.
A per-ticker accuracy statistic for KROS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, KROS included.
Follow KROS freeKROS price chart and AI forecast
How KROS ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Keros Therapeutics, Inc. (KROS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | KROS | Rank |
|---|---|---|
| Market Cap | $223M | 60/60 |
| P/B Ratio | 0.85x | 43/43 |
| EPS | $-3.22 | – |
| Book Value/Share | $13.23 | – |
| Revenue/Share | $0.73 | – |
| FCF/Share | $-2.45 | – |
Profitability & Margins
| Metric | KROS | Rank |
|---|---|---|
| ROE | -31.7% | 25/33 |
| ROA | -28.9% | 32/39 |
| ROIC | -36.8% | 30/41 |
| Operating Margin | -698.0% | 30/33 |
| Net Margin | -572.1% | 30/33 |
| EBT Margin | -592.3% | 37/40 |
| Tax Rate | 3.4% | – |
Financial Health
| Metric | KROS | Rank |
|---|---|---|
| Current Ratio | 21.96x | 5/50 |
| D/E Ratio | 0.10x | 35/43 |
| Financial Leverage | 1.10x | 36/43 |
| Interest Coverage | -4866.0x | 36/36 |
| Working Capital | $255M | 45/50 |
Cash Flow
| Metric | KROS | Rank |
|---|---|---|
| Operating Cash Flow | -$48M | 30/49 |
| Free Cash Flow | -$48M | 24/39 |
| Capital Spending | -$490K | 4/39 |
| OCF Growth YoY | -187.2% | 26/28 |
| FCF Growth YoY | -191.3% | 24/25 |
| FCF/Sales | -333.6% | 32/34 |
| CapEx/Sales | 3.4% | 15/34 |
Operational Efficiency
| Metric | KROS | Rank |
|---|---|---|
| Asset Turnover | 0.05x | 35/38 |
| Fixed Assets Turnover | 3.9x | 22/37 |
| Days Sales Outstanding | 0 days | 34/34 |
Income Statement
| Metric | KROS | Rank |
|---|---|---|
| Total Revenue | $14M | 38/39 |
| Operating Income | -$101M | 24/41 |
| Net Income | -$83M | 23/40 |
| R&D Expense | $76M | 45/48 |
Dividend & Shareholder Information
| Metric | KROS | Rank |
|---|---|---|
| Shares Outstanding | 20M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $267M | 92.9% of assets |
| Cash & Short-term Investments | $258M | 89.7% of assets |
| Accounts Receivable | $0.00M | 0.0% of assets |
| Total Liabilities | $25M | 8.8% of assets |
| Short-term Debt | $10M | 3.6% of assets |
KROS quarterly financials and insider trading
Keros Therapeutics, Inc. (KROS) industry peers
Companies classified under the same SEC industry code as Keros Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| KROS Keros Therapeutics, Inc. | ▲ | $223M |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.85B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.50B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| SNY Sanofi | ▼ | $48.46B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.98B |
| RPRX Royalty Pharma Plc | ▲ | $33.22B |
| ZTS Zoetis Inc. | ▼ | $31.26B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.72B |
| ZLAB Zai Lab Ltd | ▼ | $27.60B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.74B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.59B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $20.15B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| SMMT Summit Therapeutics Inc. | ▶ | $13.67B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.57B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $6.18B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.90B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where KROS sits on the market map
Keros Therapeutics, Inc. (KROS) stock news
Loading...
Keros Therapeutics, Inc. (KROS) stock forecast FAQ
What is the Keros Therapeutics, Inc. (KROS) stock forecast?
Our AI ranks Keros Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Keros Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for KROS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Keros Therapeutics, Inc. forecasts updated?
Keros Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Keros Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, KROS included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.